Menu Search
Equities

Neola Medical AB

NEOLA:STO

Neola Medical AB

Actions
Health CareMedical Equipment and Services
  • Price (SEK)2.00
  • Today's Change-0.02 / -0.99%
  • Shares traded29.61k
  • 1 Year change+44.93%
  • Beta1.1411
Data delayed at least 15 minutes, as of Nov 12 2024 17:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in SEKIncome statement in SEKView more

Year on year Neola Medical AB had revenues remain flat at 0.00, though the company grew net income from a loss of 10.35m to a smaller loss of 9.01m.
Gross margin--
Net profit margin--
Operating margin--
Return on assets-12.63%
Return on equity-13.81%
Return on investment-13.59%
More ▼

Cash flow in SEKView more

In 2023, cash reserves at Neola Medical AB fell by 18.51m. Cash Flow from Financing totalled 336.00k or -- of revenues. In addition the company used 6.54m for operations while cash used for investing totalled 12.31m.
Cash flow per share-0.125
Price/Cash flow per share--
Book value per share1.05
Tangible book value per share0.3575
More ▼

Balance sheet in SEKView more

Neola Medical AB has little financial risk as the capital structure does not rely on leverage.
Current ratio5.47
Quick ratio--
Total debt/total equity0.00
Total debt/total capital0.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.